Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gersizangitide - AsclepiX Therapeutics

Next Previous
Drug Profile

Gersizangitide - AsclepiX Therapeutics

Alternative Names: AXT-107

Latest Information Update: 13 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AsclepiX Therapeutics
  • Class Eye disorder therapies; Peptides
  • Mechanism of Action TIE-2 receptor agonists; Vascular endothelial growth factor A inhibitors; Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diabetic macular oedema; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 06 May 2024 AsclepiX Therapeutics completes enrolment in its phase I/II DISCOVER trial for Wet-age-related-macular-degeneration in USA (Intravitreous) (NCT05859776)
  • 19 Dec 2023 AsclepiX Therapeutics initiates enrolment in a phase I/II DISCOVER trial in Wet age-related macular degeneration in USA (Intravitreous) (NCT05859776)
  • 26 Jul 2023 AsclepiX Therapeutics plans phase I/II DISCOVER trial for Wet age-related macular degeneration in January 2024 (Intravitreous) (NCT05859776)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top